STEMCELL-TECHNOLOGIES
18.8.2021 12:02:03 CEST | Business Wire | Press release
STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use of tissue-derived organoids—including lung, intestinal, and liver organoids—for use in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL. These services will help researchers and organizations working on drug development incorporate organoids into their preclinical testing programs and bring new therapeutics to market faster and more cost-effectively.
HUB Organoids™ are experimental models derived from the adult stem cells present in epithelial tissues. Expansion and differentiation of these stem cells gives rise to functional “mini-organs in a dish”. HUB Organoids™ represent a patient-specific way of assessing the efficacy and toxicity of drugs during preclinical screening. By closely mimicking human biology, HUB Organoids™ can be used to more accurately predict patient response to treatment than traditionally used systems. As such, they have the potential to drastically lower the costs and failure rates currently associated with bringing new treatments to market. Under the existing agreement, STEMCELL develops and supplies a wide range of cell culture kits that efficiently expand and maintain the different stem cell-derived organoids that will be used for many of these screening programs.
This new agreement complements HUB and STEMCELL’s existing partnership, where STEMCELL is the exclusive provider of cell culture media for all HUB Organoids™, by allowing STEMCELL to perform preclinical toxicology screening as well as non-cancer drug testing and validation services. "We are extremely pleased to be able to expand our partnership with HUB to include these new services," remarked Dr. Allen Eaves, STEMCELL’s Founder, President, and CEO. "As Scientists Helping Scientists, our goal is to make these incredible technologies more accessible to researchers, whether they are growing organoids in their own labs or partnering with service providers to advance their science."
“At HUB we are on a mission to bridge the gap between the lab and the clinic and bring patients-specific models into the lab,” said Dr. Robert Vries, HUB CEO. “Carefully selecting our strategic partners is key to expanding global access to HUB Organoid Technology and, ultimately, to improving patient care. STEMCELL has already demonstrated thought leadership in the Organoid Technology field; therefore, we believe that expanding the scope of our partnership to include services will benefit the research and drug development community worldwide.”
About STEMCELL Technologies
As Scientists Helping Scientists, STEMCELL Technologies is committed to providing high-quality cell culture media, cell isolation products, accessory reagents and services for life science research. Driven by science and a passion for quality, STEMCELL Technologies offers over 2500 products designed to support the basic to translational research continuum. Visit www.stemcell.com to learn more.
About HUB
Hubrecht Organoid Technology (HUB) was founded by the Hubrecht Institute, the University Medical Center Utrecht, and the Royal Netherlands Academy of Arts and Sciences (KNAW) to refine organoid development and foster organoid adoption globally. HUB Organoid Technology represents a paradigm-shift that bridges the gap between the lab and the clinic and effectively brings “patients in the lab” for drug discovery and development, preclinical patient stratification, predictive biomarker discovery, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics applications. Learn more by visiting www.huborganoids.nl
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005144/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global udvider sine juridiske kompetencer gennem samarbejde med Beech Incorporated13.8.2026 18:01:00 CEST | Pressemeddelelse
Andersen Global indgår en samarbejdsaftale med det sydafrikanske advokatfirma Beech Incorporated og udvider dermed sine juridiske kompetencer i regionen. Beech Incorporated leverer juridisk og regulatorisk rådgivning til mine-, vedvarende energi-, infrastruktur-, olie- og gassektorerne med speciale inden for fusioner og opkøb, kommercielle forhold, projektfinansiering, sundhed, sikkerhed og miljø, ansættelsesret samt compliance. Firmaets tværfaglige team rådgiver klienter gennem hele projektets livscyklus – fra udvikling og finansiering til drift og interessenthåndtering – og er anerkendt som et førende advokatfirma af blandt andre publikationer somChambers and Partners og The Legal 500 . "Vores tilgang bygger på en praktisk forståelse af de brancher, vi arbejder inden for, og på at levere konkret og handlingsorienteret rådgivning til klienter, der opererer i komplekse regulatoriske miljøer," siger Warren Beech, der er CEO for Beech Incorporated. "Gennem samarbejdet med Andersen Global
BTG Pactual TIG and Conservation International Reach 20,000 Hectares of Cerrado UnderRestoration, Accelerating Latin American Reforestation Strategy, Increasing Biodiversity andSocial Impacts13.8.2026 17:47:00 CEST | Press release
BTG Pactual Timberland Investment Group (BTG Pactual TIG) and Conservation International today announced that native ecosystem restoration is now underway across more than 20,000 hectares of Brazil's Cerrado biome, marking a significant acceleration of the firms' Latin American reforestation strategy. According to data recorded by the Brazilian Restoration and Reforestation Observatory, an independent platform that tracks and maps native vegetation recovery, this further cements the strategy’s position as the largest ever restoration effort in the region. Conservation International serves as Impact Adviser for social and environmental outcomes. The strategy focuses on conserving, restoring and reforesting degraded landscapes across Latin America, including Brazil's Cerrado, one of the world’s most biodiverse and fastest disappearing seasonally dry ecosystems. More than half of the Cerrado has already been cleared for cattle ranching and farming. The strategy targets degraded cattle pas
Milliman names Jim Fulton next CEO13.8.2026 17:40:00 CEST | Press release
Fulton to assume CEO role in October after 11 years as CFO Milliman, Inc., a leading global actuarial and consulting firm, today announced that Jim Fulton has been named Milliman’s next Chief Executive Officer. Fulton has served as Milliman’s Chief Financial Officer since 2015 and has been a leader driving the firm’s organic growth and M&A strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811027168/en/ Milliman, Inc., a leading global actuarial and consulting firm, today announced that Jim Fulton has been named Milliman’s next Chief Executive Officer. Fulton has served as Milliman’s Chief Financial Officer since 2015 and has been a leader driving the firm’s organic growth and M&A strategy. Fulton’s appointment reflects Milliman’s evolution from an actuarial firm to a multidisciplinary consultancy, risk management, and technology solution provider. His expertise includes stints with Big 4 accounting and private equi
Clinilabs Announces Leadership Expansion and Welcomes Laura Shannon as Chief Executive Officer and Promotion of Founder Gary Zammit, Ph.D., to Executive Chairperson13.8.2026 16:05:00 CEST | Press release
Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced leadership expansion. Laura Shannon joins the organization as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson. This expansion of the senior leadership team is a recognition of a growing organization with global capabilities and continuing commitment to advancing treatments for patients with psychiatric and neurological disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813362140/en/ Laura Shannon joins Clinilabs as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson Ms. Shannon is a dynamic leader with more than 30 years of biopharma industry experience, known for her ability to build high-performing teams, forge strategic alliances, and drive
Resurgens Technology Partners Invests in Qarma to Advance the Future of Quality and Compliance13.8.2026 15:00:00 CEST | Press release
Partnership brings together Resurgens' software investing expertise and Qarma’s leading quality and compliance platform to accelerate product innovation and expand its reach across North America, Europe, and Asia Resurgens Technology Partners (“Resurgens”), a software-focused private equity firm, today announced its partnership with Qarma, a leading global provider of AI-powered quality and compliance software for brands, retailers, and manufacturers managing complex, global supply chains. Qarma has built a platform that combines best-practice quality and compliance with hands-on execution where it matters most, on the factory floor. Qarma will continue to be led by its Co-founders, CEO Jacob Nedergaard and CTO Søren Mønsted. Founded in 2016, Qarma serves customers across industries, including furniture and home, apparel, consumer goods, and electronics. Its platform connects quality and compliance teams, sourcing professionals, suppliers, and inspectors. Over the past decade, Qarma ha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom